Sutro Biopharma Stock (NASDAQ:STRO)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$2.70

52W Range

$2.13 - $6.13

50D Avg

$3.71

200D Avg

$3.99

Market Cap

$220.16M

Avg Vol (3M)

$600.29K

Beta

1.17

Div Yield

-

STRO Company Profile


Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

302

IPO Date

Sep 27, 2018

Website

STRO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 18
Other Revenue$5.42M
Collaboration Revenue$13.54M

Fiscal year ends in Dec 23 | Currency in USD

STRO Financial Summary


Dec 23Dec 22Dec 21
Revenue$153.73M$67.77M$61.88M
Operating Income$-89.28M$-128.94M$-98.52M
Net Income$-106.79M$-119.20M$-108.67M
EBITDA$-82.46M$-125.49M$-93.10M
Basic EPS$-1.78$-2.35$-2.36
Diluted EPS$-1.78$-2.35$-2.36

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
ANABAnaptysBio, Inc.
IDYAIDEAYA Biosciences, Inc.
CNTACentessa Pharmaceuticals plc
MRUSMerus N.V.
LRMRLarimar Therapeutics, Inc.
MLYSMineralys Therapeutics, Inc.
MGTXMeiraGTx Holdings plc
HLVXHilleVax, Inc.
AVTEAerovate Therapeutics, Inc.
REPLReplimune Group, Inc.
SNDXSyndax Pharmaceuticals, Inc.
KROSKeros Therapeutics, Inc.
PCVXVaxcyte, Inc.
GNTAGenenta Science S.p.A.
FIXXQ32 Bio Inc.
PRDSPardes Biosciences, Inc.
OPTOpthea Limited
ELYMEliem Therapeutics, Inc.